Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579527 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Thymus Transplantation With Immunosuppression #950
A Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00579527: Completed Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
NCT00579527 is a Phase 1 study that has completed, run by Sumitomo Pharma Switzerland. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00579527, a Phase 1 study, has completed, sponsored by Sumitomo Pharma Switzerland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also evaluate whether cultured thymus tissue implantation and parathyroid transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly and hypoparathyroidism.
Primary Outcome
Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.
Interventions
- PROCEDURE Blood Draw
- DRUG Cyclosporine
- DRUG Rabbit anti-thymocyte globulin
- BIOLOGICAL Cultured Thymus Tissue for Implantation (CTTI)
- OTHER Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-12-19 |
| Est. Completion | 2017-12-31 |
| Phase | Phase 1 |
What the finished NCT00579527 record still lists
NCT00579527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which Blood Draw is the first listed.
NCT00579527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00579527 about?
NCT00579527 is a clinical study titled "Phase I/II Thymus Transplantation With Immunosuppression #950". The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also ...
What is the current status of trial NCT00579527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-12-19. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT00579527?
The interventions under investigation include: Blood Draw (PROCEDURE), Cyclosporine (DRUG), Rabbit anti-thymocyte globulin (DRUG), Cultured Thymus Tissue for Implantation (CTTI) (BIOLOGICAL), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation (OTHER).
Who is sponsoring clinical trial NCT00579527?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00579527's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy